Spyre Therapeutics, Inc. (SYRE) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Waltham, MA, 미국. 현재 CEO는 Cameron Turtle.
SYRE 을(를) 보유 IPO 날짜 2016-04-07, 73 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $4.17B.
Spyre Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company's lead candidate, SPY001, is a human monoclonal antibody targeting the α4β7 integrin, designed to selectively treat IBD patients. Spyre's pipeline also includes SPY002, which targets tumor necrosis factor-like ligand 1A, along with several combination and early-stage programs such as SPY003 (anti-IL-23), SPY004, and various combination therapies currently in preclinical development. Incorporated in 2013 and headquartered in Waltham, Massachusetts, the company was formerly known as Aeglea BioTherapeutics before rebranding to Spyre Therapeutics in November 2023.
